CN1951464A - Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof - Google Patents
Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof Download PDFInfo
- Publication number
- CN1951464A CN1951464A CN 200610017297 CN200610017297A CN1951464A CN 1951464 A CN1951464 A CN 1951464A CN 200610017297 CN200610017297 CN 200610017297 CN 200610017297 A CN200610017297 A CN 200610017297A CN 1951464 A CN1951464 A CN 1951464A
- Authority
- CN
- China
- Prior art keywords
- thick paste
- preparation
- standby
- fine powder
- beauv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 5
- 150000001875 compounds Chemical class 0.000 title claims description 7
- 239000003814 drug Substances 0.000 claims abstract description 24
- 241000325845 Leontopodium leontopodioides Species 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 16
- 239000008589 Cortex Fraxini Substances 0.000 claims description 13
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- -1 filtered Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 9
- 231100000614 poison Toxicity 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002574 poison Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 239000003440 toxic substance Substances 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 210000001015 abdomen Anatomy 0.000 claims description 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010014080 Ecchymosis Diseases 0.000 claims 1
- 206010048245 Yellow skin Diseases 0.000 claims 1
- 206010016766 flatulence Diseases 0.000 claims 1
- 208000027692 gas pain Diseases 0.000 claims 1
- 201000005630 leukorrhea Diseases 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 238000005096 rolling process Methods 0.000 claims 1
- 210000005182 tip of the tongue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 206010046901 vaginal discharge Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 4
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 235000007650 Aralia spinosa Nutrition 0.000 abstract 1
- 241000234653 Cyperus Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000299492 Thespesia populnea Species 0.000 abstract 1
- 235000009430 Thespesia populnea Nutrition 0.000 abstract 1
- 241000949456 Zanthoxylum Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000008961 swelling Effects 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000019802 Sexually transmitted disease Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 210000004303 peritoneum Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000226555 Leontopodium Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000010669 pelvic lump Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese pharmaceutical composition for treating gynaecologic inflammation, process for preparation, the use and main pharmacodynamic research result, wherein the formula of the medicament includes Leontopodium leontopodioides 30-500g, yellow corktree bark 15-300g, ash bark 25-450g, shiny pricklyash 30-400g, red peony root 20-300g, and nutgrass flatsedge rhizome 1-200g.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation that is used for gynecopathy therapeutic, relate to a kind of Chinese traditional compound medicine that the evil stasis of blood of damp and hot poison is forged the chronic pelvic inflammatory disease of burnt syndrome, bacterial vaginitis treatment that is used for specifically.
Background technology
Pelvic inflammatory disease is the gynaecopathia usually seen of chronic pelvic inflammatory disease right and wrong especially, and its sickness rate is the trend that increases gradually in recent years.In China, because the restriction of Personal hygiene condition and medical condition, or sterile working's idea is indifferent in gynecological's minor operation and family planning operation, and the patient does not note reasons such as Personal hygiene during the extensive use intrauterine device in addition, makes the sickness rate of pelvic inflammatory disease very high.Frequent day by day along with foreign exchanges, sexually transmitted disease (STD) is the trend that raises year by year at the sickness rate of China, and therefore the pelvic inflammatory disease that causes is also increasing.This situation is thin in sex consciousness, and sexual life is chaotic so that area that sexually transmitted disease (STD) is occurred frequently is more obvious.Chronic pelvic inflammatory disease is often failed thoroughly treatment for acute pelvic inflammatory disease in addition, or due to the weak course of disease delay of plain body, and what have is secondary to more serious chronic cervicitis, vaginitis.Clinical manifestation is with hypogastralgia repeatedly, and lumbosacral aching pain, leucorrhoea grow in quantity etc. are main, symptom such as often tired with menoxenia, low grade fever, susceptible, pelvic lump, sexual anhedonia.It is long to have the course of disease, and the state of an illness is touching, characteristics such as relapse rate height.According to the clinical manifestation of primary disease, chronic pelvic inflammatory disease belongs to the traditional Chinese medical science " lower abdominal pain ", " leukorrheal diseases ", " menoxenia ", “ mass in the abdomen " etc. category.According to the clinical research report, modern medicine does not have definite curative effect as yet for the treatment of chronic pelvic inflammatory disease at present, and the dialectical advantage in conjunction with differential diagnosis of diseases of modern TCM makes the traditional Chinese medical science in the treatment for the research chronic pelvic inflammatory disease certain progress be arranged.And bacterial vaginosis is the commonly encountered diseases in the department of obstetrics and gynecology outpatient service, and sickness rate is higher, and main clinic symptoms is a leucorrhoea grow in quantity, and pudendal pruritus brings very big inconvenience for patient's life.No specificity medication before its treatment, therapeutic effect is not obvious.Present situation based on present integrative therapy chronic pelvic inflammatory disease and bacterial vaginitis, our seminar is according to year clinical experience surplus 20, think that mostly the generation of primary disease is owing in deficiency of qi and blood such as capable puerperal, damp and hot malicious heresy goes into uterus and blood is tied the retardance vessels of the uterus mutually, and it is not smooth to cause the vessels of the uterus QI-blood circulation, stops up in the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, causes the card of the evil stasis of blood knot of damp and hot poison, treatment is worked as with heat-clearing and toxic substances removing dampness, and blood-activating analgetic is a method.
Summary of the invention
The objective of the invention is to develop a kind of medicine for the treatment of gynaecopathia effectively, comprising composition, preparation method, purposes and the pharmacodynamic study result of medicine.
Advantage of the present invention is: this product is pure compound Chinese medicinal preparation, on the basis of comprehensive multiple treatment medicine for gynecopathy that square Chinese medicine is organic, dialectical ground compatibility together, Leontopodium leontopodioides (Willd.) Beauv. bitter cold in the side, heat-clearing and toxic substances removing removing heat from blood dampness removing is monarch, minister is with Cortex Phellodendri, Cortex Fraxini heat clearing and damp drying pathogenic fire detoxifcation leukorrhagia stopping, the effect of principal drug assistance performance damp eliminating pyrolysis fire-toxin, assistant is with Radix Paeoniae Rubra, Radix Zanthoxyli blood-activating analgetic, and QI and blood regulating gets freely mechanism of qi, blood stasis must be capable, damp and hot clearly, make with the Rhizoma Cyperi priming and return liver, make wind wood not inaccessible in ground, then in the sky, be good for and be with from disappearing by temper from ascension for ground vapour.All medicines share and make that damp and hot poison is evil must to be removed, QI-blood circulation gets freely, and all disease rehabilitations of the female section of woman are so the burnt syndrome of chronic pelvic inflammatory disease, bacterial vaginitis treatment this product is forged to(for) the evil stasis of blood of damp and hot poison have unique curative effect, its pharmacodynamics and toxicity research result show that also toxic and side effects is little, take safe and effective.
The objective of the invention is to realize by following measure:
1, a kind of compound Chinese medicinal preparation that is used for the treatment of gynaecopathia, the pharmaceutical preparation of forming by following Chinese medicinal raw materials in proportion by weight:
Leontopodium leontopodioides (Willd.) Beauv. (Leontopodium leontopdioides (wils) Beauv.) 30-500g
Cortex Phellodendri (cortex phellodendri amurensis) 15-300g
Cortex Fraxini (cortex fraxini) 25-450g
Radix Zanthoxyli (radix zanthoxyli) 30-400g
Radix Paeoniae Rubra (radix paeoniae rubra) 20-300g
Rhizoma Cyperi (rhizoma cyperi) 1-200g
2, the preferred proportion of compound Chinese medicinal preparation is (latin name is slightly):
Leontopodium leontopodioides (Willd.) Beauv. 345g Cortex Phellodendri 215g Cortex Fraxini 360g
Radix Zanthoxyli 295g Radix Paeoniae Rubra 260g Rhizoma Cyperi 105g
3, preparation method:
Six-element in the side, Rhizoma Cyperi is ground into fine powder, and is standby.Cortex Phellodendri, Cortex Fraxini, Radix Zanthoxyli are ground into coarse powder, add 6 times of amount 70% ethanol extractions 2 times, and each 3 hours, merge extractive liquid, filtered, and filtrate recycling ethanol also is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), and is standby.All the other Leontopodium leontopodioides (Willd.) Beauv., Radix Paeoniae Rubra two flavors add 10 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate decompression is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), adds above-mentioned fine powder and thick paste, mixing, drying is pulverized, add appropriate amount of starch, mixing is with 95% ethanol system granule, dry, granulate is made solid preparation, promptly.
4, Pharmacodynamic test of active extract
4.1 the influence of rat paw edema due to the on Carrageenan
Get 50 of rats, raise after 2 days, be divided into five groups at random, 10 every group.Press the gastric infusion of dosage shown in the table 1, once a day, continuous three days, 1h after the last administration, 1% carrageenin (0.1ml/ only) injected under the right back sufficient plantar aponeurosis of rat successively cause inflammation, measured rat paw and ankle joint circumference every 1 hour with self-control arrowband chi, compare with left back foot, with about the sufficient sole of the foot and ankle joint circumference and difference be the swelling degree.The results are shown in Table 1.
The influence of rat paw edema due to table 1 this product on Carrageenan
Group | G crude drug/kg | Number of animals n | Normally | Different time (h) foot swelling degree (mm behind the injection carrageenin; X ± SD) | ||||
1 | 3 | 4 | 5 | |||||
Matched group FUYANKANG PIAN this product capsule this product capsule this product capsule | - 2.43g/kg 14.52 7.26 3.63 | 10 10 10 10 10 | 40.8±2.08 41.05±1.69 40.65±1.53 41.10±1.15 42.00±1.68 | 3.30±0.86 4.35±1.27* 4.35±1.31* 2.45±0.83** 2.55±1.12 | 5.40±1.43 3995±1.44* 3.85±1.75* 4.40±1.43 4.35±1.13*** | 8.80±1.09 6.75±2.70* 6.4O±2.22** 7.10±2.73 7.35±2.07** | 10.65±0.85 9.80±1.03* * 8.45±2.54* 8.65±3.26 9.55±1.66* * | 9.75±3.68 7.25±2.45** 7.25±2.15 7.50±3.11 7.40±2.16** |
*<0.05,**p<0.01,***p<0.001
The result shows, behind the injection carrageenin, each dosage group of this product all demonstrates has in various degree inhibitory action to rat paw edema, remarkable with the matched group comparing difference.
4.2 xylol causes the influence of mice auricle swelling
Get 50 of mices, be divided into five groups at random.Dosage gastric infusion as shown in table 2, every day 1 time, continuous 3 days, 1h behind the last medicine, the two sides is coated with the dimethylbenzene (100%) of 0.1ml before and after each Mus left side ear, auris dextra is as own control, animal is put to death in the cervical vertebra dislocation behind the 4h, with diameter 9mm diameter card punch, lays round auricle in each Mus left and right sides ear same area, left and right sides auricle weight difference is the swelling degree, calculates swelling degree and inhibitory rate of intumesce.The results are shown in Table 2.
Table 2 this product xylol causes the influence of mice auricle swelling
*P<0.05
The result as seen, this product can obviously suppress the mice auricle swelling that caused by dimethylbenzene.
4.3 mice acetic acid is caused the influence of peritoneum inflammatory exudation
Get 50 of mices, be divided into five groups at random, press the gastric infusion of dosage shown in the table 3, every day 1 time, continuous 3 days.1h behind the last medicine, mouse tail vein injection 0.5% azovan blue (0.2ml/ Mus), and lumbar injection 0.6% acetic acid (0.2ml/ Mus) immediately, injection back 30min puts to death mice, uses the normal saline flushing abdominal cavity, collects whole flushing liquors to 10ml, get supernatant after centrifugal and measure the OD value in 630nm wavelength place, with the concentration of azovan blue in the OD value representation flushing liquor, reflect the degree of peritoneum inflammatory exudation indirectly, the results are shown in Table 3.
Table 3 this product causes the influence of peritoneum inflammatory exudation to mice acetic acid
Group | G crude drug/kg | Number of animals n | OD value X ± SD | Suppression ratio (%) |
Matched group FUYANKANG PIAN this product 20.97 this product 10.49 this product 5.25 | - 3.51g/kg | 10 10 10 10 10 | 0.424±0.109 0.275±0.117** 0.284±0.102** 0.300±0.143* 0.390±0.115 | 35.14 33.02 29.25 8.02 |
*<0.05.**p<0.01
The result as seen, the OD value of this product height, middle dosage group all is lower than matched group, significant difference illustrates that this product causes the peritoneum inflammatory exudation to mice acetic acid certain inhibitory action is arranged.
5, acute toxicity testing:
This product is not less than 225.20g crude drug/kg for the mouse stomach maximum dosage-feeding with Cmax 1.88g crude drug/ml, maximum volume 0.4ml/10g body weight, observed 15 after the administration, do not observe 15 after seeing toxic reaction and dead medicine, do not have drug-induced acute toxic reaction and death.
6, in conjunction with the embodiments the present invention is further described, but the present invention is not subjected to any restriction of embodiment.
Embodiment 1 (tablet)
Prescription:
Leontopodium leontopodioides (Willd.) Beauv. 345g Cortex Phellodendri 215g Cortex Fraxini 360g
Radix Zanthoxyli 295g Radix Paeoniae Rubra 260g Rhizoma Cyperi 105g
Method for making:
Six-element in the side, Rhizoma Cyperi is ground into fine powder, and is standby.Cortex Phellodendri, Cortex Fraxini, Radix Zanthoxyli are ground into coarse powder, add 6 times of amount 70% ethanol extractions 2 times, and each 3 hours, merge extractive liquid, filtered, and filtrate recycling ethanol also is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), and is standby.All the other Leontopodium leontopodioides (Willd.) Beauv., Radix Paeoniae Rubra two flavors add 10 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate decompression is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), adds above-mentioned fine powder and thick paste, mixing, drying is pulverized, add appropriate amount of starch, mixing is with 95% ethanol system granule, drying, granulate, tabletting, the bag film-coat is made 1000, promptly.
Embodiment 2 (capsule)
Prescription:
Leontopodium leontopodioides (Willd.) Beauv. 345g Cortex Phellodendri 215g Cortex Fraxini 360g
Radix Zanthoxyli 295g Radix Paeoniae Rubra 260g Rhizoma Cyperi 105g
Method for making:
Six-element in the side, Rhizoma Cyperi is ground into fine powder, and is standby.Cortex Phellodendri, Cortex Fraxini, Radix Zanthoxyli are ground into coarse powder, add 6 times of amount 70% ethanol extractions 2 times, and each 3 hours, merge extractive liquid, filtered, and filtrate recycling ethanol also is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), and is standby.All the other Leontopodium leontopodioides (Willd.) Beauv., Radix Paeoniae Rubra two flavors add 10 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate decompression is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), adds above-mentioned fine powder and thick paste, mixing, drying is pulverized, add appropriate amount of starch, mixing is with 95% ethanol system granule, drying, granulate, encapsulated, make 1000, promptly.
Claims (5)
1, a kind of Chinese traditional compound medicine that is used for the treatment of gynecological inflammation is characterized in that it is to be made by following raw material:
Leontopodium leontopodioides (Willd.) Beauv. 30-500g Cortex Phellodendri 15-300g Cortex Fraxini 25-450g
Radix Zanthoxyli 30-400g Radix Paeoniae Rubra 20-300g Rhizoma Cyperi 1-200g.
2, Chinese medicine preparation according to claim 1 is characterized in that it is to be made by the following weight proportion raw material:
Leontopodium leontopodioides (Willd.) Beauv. 345g Cortex Phellodendri 215g Cortex Fraxini 360g
Radix Zanthoxyli 295g Radix Paeoniae Rubra 260g Rhizoma Cyperi 105g.
3, the preparation method of Chinese medicine preparation according to claim 1 and 2 is characterized in that:
A, Rhizoma Cyperi are ground into fine powder, and be standby;
B, Cortex Phellodendri, Cortex Fraxini, Radix Zanthoxyli are ground into coarse powder, add 3-10 and doubly measure the 30-80% ethanol extraction 2 times, and each 2-3 hour, merge extractive liquid, filtered, and filtrate recycling ethanol also is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), and is standby;
C, Leontopodium leontopodioides (Willd.) Beauv., Radix Paeoniae Rubra add 6-12 times of water gaging and decoct 2-3 time, and each 1-3 hour, collecting decoction filtered, and filtrate decompression is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), and is standby;
D, fine powder and thick paste that above-mentioned a, b and C item are made, mixing, drying is pulverized, and adds appropriate amount of starch, mixing, with 50%~95% ethanol system granule, drying, granulate is made solid preparation, promptly.
4, the preparation method of Chinese medicine preparation according to claim 3 is characterized in that:
A, Rhizoma Cyperi are ground into fine powder, and be standby;
B, Cortex Phellodendri, Cortex Fraxini, Radix Zanthoxyli are ground into coarse powder, add 6 times of amount 70% ethanol extractions 2 times, and each 3 hours, merge extractive liquid, filtered, and filtrate recycling ethanol also is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), and is standby;
C, Leontopodium leontopodioides (Willd.) Beauv., Radix Paeoniae Rubra add 10 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction filtered, and filtrate decompression is concentrated into the thick paste that relative density is 1.30~1.35 (60 ℃), adds above-mentioned fine powder and thick paste, and is standby;
D, with fine powder and thick paste mixing that above-mentioned a, b and C item make, drying is pulverized, and adds appropriate amount of starch, mixing, with 95% ethanol system granule, drying, granulate is made solid preparation, promptly.
5, has heat-clearing and toxic substances removing dampness, the effect of blood-activating analgetic according to claim 1 and 2 described Chinese medicine preparation.Being mainly used in Chinese medical discrimination belongs to the evil stasis of blood of damp and hot poison and forges the chronic pelvic inflammatory disease of burnt syndrome, the treatment of bacterial vaginitis.Disease is seen: pudendal pruritus, profuse leukorrhea, yellow skin matter are thick, inferior belly gas pain or twinge, and abdominal pain in menstruation increases the weight of, lumbus sacrum pain, and yellow urine is hard and dry or half congealed and not well, red tongue or dark red, or purple spots at the margin and tip of the tongue or ecchymosis, yellow and greasy fur or white greasy, stringy and rolling pulse or string are puckery.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100172978A CN100455309C (en) | 2006-11-03 | 2006-11-03 | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100172978A CN100455309C (en) | 2006-11-03 | 2006-11-03 | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1951464A true CN1951464A (en) | 2007-04-25 |
CN100455309C CN100455309C (en) | 2009-01-28 |
Family
ID=38058145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100172978A Expired - Fee Related CN100455309C (en) | 2006-11-03 | 2006-11-03 | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100455309C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101822735A (en) * | 2010-05-24 | 2010-09-08 | 吉林大学 | Medicine composite treating colpitis and preparation method of corresponding foam spraying agent |
CN102357168A (en) * | 2011-10-10 | 2012-02-22 | 赵全成 | Chinese medicinal composition for treating gynecological diseases and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1820780A (en) * | 2005-02-19 | 2006-08-23 | 李砚秋 | Method for preparing Fuyankang extract |
-
2006
- 2006-11-03 CN CNB2006100172978A patent/CN100455309C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101822735A (en) * | 2010-05-24 | 2010-09-08 | 吉林大学 | Medicine composite treating colpitis and preparation method of corresponding foam spraying agent |
CN102357168A (en) * | 2011-10-10 | 2012-02-22 | 赵全成 | Chinese medicinal composition for treating gynecological diseases and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100455309C (en) | 2009-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102772781B (en) | Traditional Chinese medicine preparation for treating chronic colitis and preparation method thereof | |
CN100382815C (en) | Compound composition for treating arthralgia caused by wind-dampness and preparation thereof | |
CN101732668A (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
CN103341135A (en) | Gel agent for treating arthralgia and preparing method thereof | |
CN101007157A (en) | Traditional Chinese medicine compound preparation for treating chronic cholecystitis | |
CN102462825A (en) | Compound traditional Chinese medicine for treating depression | |
CN100455309C (en) | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof | |
CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
JP7157253B2 (en) | Chinese herbal composition for enema constipation, its preparation method and its use | |
CN103977370A (en) | Pharmaceutical composition with effect of inducing diuresis to alleviate edema | |
CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
CN103520331B (en) | Traditional Chinese medicinal preparation for treating liver-stomach disharmony type chronic gastritis and preparation method for traditional Chinese medicinal preparation | |
CN104800675A (en) | Medicament for treating active ulcerative colitis | |
CN101632729B (en) | Application of Chinese medicinal composition in preparing medicament for treating involution syndrome | |
CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
CN104000907A (en) | Traditional Chinese medicine for treating chronic urticaria and preparation method thereof | |
CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
CN108938718A (en) | A kind of preparation method of Chinese medicine composition and its preparation for treating headstroke | |
CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
CN102058764B (en) | Medicinal composition for treating acquired immune deficiency syndrome (AIDS) and application thereof | |
CN102861302B (en) | Traditional Chinese preparation for treating benign prostatic hyperplasia and preparation method for traditional Chinese preparation | |
CN102961680B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
CN102961677B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
CN104888140A (en) | Traditional Chinese medicine preparation for treatment of wind-heat skin-accumulating type pityriasis rosea and preparation method of traditional Chinese medicine preparation | |
CN105168774A (en) | Traditional Chinese medicine preparation for treating scapulohumeral periarthritis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160105 Address after: 130103, Shunda road 1369, hi tech Zone, Jilin, Changchun Patentee after: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. Address before: 130021 No. 509 Mao Xiang street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: Zhao Quancheng |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090128 Termination date: 20181103 |